Skip to main content

Clinical Investigations in Brazil (RDC 10/2015)

BR-unique

Brazil regulates clinical investigations of medical devices through RDC 10/2015, a dedicated regulation setting out requirements for investigation design, ethics approval, investigational site qualification, and ANVISA notification.

RequirementDetail
ANVISA notificationMust be notified to ANVISA before commencement
Ethics committee (CEP) approvalRequired for each investigational site
CONEP approvalRequired for multicentric studies and certain high-risk investigations
GCP complianceICH GCP and ANVISA's own GCP resolution
REBEC registrationBrazilian Clinical Trials Registry — public disclosure required

Official sources

Verify all information against official ANVISA sources before making regulatory decisions.